129 related articles for article (PubMed ID: 2471010)
1. Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse.
Krupp MN; Hoover KW; Valentine JJ
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S11-8; discussion S18-9. PubMed ID: 2471010
[TBL] [Abstract][Full Text] [Related]
2. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster.
Jansen H; Lammers R; Baggen MG; Birkenhäger JC
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S5-9; discussion S9-10. PubMed ID: 2471016
[TBL] [Abstract][Full Text] [Related]
3. Effects of doxazosin and propranolol administration on lipoprotein lipases in cholesterol-fed rats.
Jansen H; Baggen RG
J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S16-20. PubMed ID: 2447435
[TBL] [Abstract][Full Text] [Related]
4. Effects of doxazosin on diet-induced hypercholesterolemia in C57BR/cdJ mice.
Swindell AC; Valentine JJ
Am J Cardiol; 1987 May; 59(14):29G-34G. PubMed ID: 2884850
[TBL] [Abstract][Full Text] [Related]
5. Influence of doxazosin on lipid transport in rats and hamsters.
Ontko JA; Woodside WF
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S31-6; discussions 36-7. PubMed ID: 2471013
[TBL] [Abstract][Full Text] [Related]
6. Effect of doxazosin on plasma lipids and atherogenesis: a preliminary report.
Kowala MC; Nicolosi RJ
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S45-9; discussion S49. PubMed ID: 2471015
[TBL] [Abstract][Full Text] [Related]
7. Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster.
Jansen H; Birkenhäger JC
J Cardiovasc Pharmacol; 1991 Sep; 18(3):354-60. PubMed ID: 1720835
[TBL] [Abstract][Full Text] [Related]
8. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Pool JL
Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
[TBL] [Abstract][Full Text] [Related]
9. Effects of adrenoreceptor antagonists and agonists on clearance of emulsion models of triacylglycerol-rich lipoproteins from plasma in rats.
Mackintosh VS; Elsegood CL; Redgrave TG
Clin Exp Pharmacol Physiol; 1991 Nov; 18(11):775-88. PubMed ID: 1685947
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatic cholesterol synthesis by the alpha 1-adrenoceptor blocker doxazosin in the hypercholesterolemic golden hamster.
Jansen H; Lammers R; Baggen MG; Penders JM; Birkenhäger JC
Life Sci; 1989; 44(15):1013-7. PubMed ID: 2564614
[TBL] [Abstract][Full Text] [Related]
11. Studies with doxazosin on the saturable binding of 125I-LDL by liver in normocholesterolemic mice.
Nanjee MN; Miller NE
J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S35-41. PubMed ID: 2447439
[TBL] [Abstract][Full Text] [Related]
12. Chronic alpha 1-adrenergic blockade, serum triacylglycerols, and tissue lipoprotein lipase activity in rats fed diets high in starch or sucrose.
Deshaies Y; Martineau MJ; LaLonde J
Nutrition; 1991; 7(2):109-15; discussion 115-6. PubMed ID: 1686980
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.
Grimm RH; Flack JM; Grandits GA; Elmer PJ; Neaton JD; Cutler JA; Lewis C; McDonald R; Schoenberger J; Stamler J
JAMA; 1996 May 22-29; 275(20):1549-56. PubMed ID: 8622245
[TBL] [Abstract][Full Text] [Related]
14. Doxazosin: a new alpha 1-adrenergic antagonist.
Babamoto KS; Hirokawa WT
Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
[TBL] [Abstract][Full Text] [Related]
15. Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
Karge WH; Kowala MC; Weiner EJ; Nicolosi RJ
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S25-9; discussion S29-30. PubMed ID: 2471012
[TBL] [Abstract][Full Text] [Related]
16. Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters.
Kowala MC; Nunnari JJ; Durham SK; Nicolosi RJ
Atherosclerosis; 1991 Nov; 91(1-2):35-49. PubMed ID: 1687433
[TBL] [Abstract][Full Text] [Related]
17. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
Pool JL; Taylor AA; Nelson EB
Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
[TBL] [Abstract][Full Text] [Related]
18. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
Pool JL; Lenz ML; Taylor AA
J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
[TBL] [Abstract][Full Text] [Related]
19. Effects of doxazosin, an alpha 1-adrenergic inhibitor, on plasma lipid and lipoprotein levels, low density lipoprotein metabolism and cholesterol absorption in cynomolgus monkeys.
Stucchi AF; Vespa DB; Terpstra AH; Nicolosi RJ
Atherosclerosis; 1993 Nov; 103(2):255-66. PubMed ID: 8292100
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing the lipid response to selective alpha 1-inhibition.
Dzau VJ
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S50-2; discussion S52. PubMed ID: 2471017
[No Abstract] [Full Text] [Related]
[Next] [New Search]
